Justesen US - Search Results

1

Changing incidence of central nervous system diseases in the EuroSIDA cohort.

d'Arminio Monforte A, Cinque P, Mocroft A, Goebel FD, Antunes F, Katlama C, Justesen US, Vella S, Kirk O, Lundgren J; EuroSIDA Study Group. d'Arminio Monforte A, et al. Among authors: justesen us. Ann Neurol. 2004 Mar;55(3):320-8. doi: 10.1002/ana.10827. Ann Neurol. 2004. PMID: 14991809

2

Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials.

Justesen US, Fox Z, Pedersen C, Cahn P, Gerstoft J, Clumeck N, Losso M, Peters B, Obel N, Castagna A, Dragsted UB, Lundgren JD; MaxCmin1 and 2 trial groups. Justesen US, et al. Basic Clin Pharmacol Toxicol. 2007 Nov;101(5):339-44. doi: 10.1111/j.1742-7843.2007.00117.x. Basic Clin Pharmacol Toxicol. 2007. PMID: 17910618 Free article. Clinical Trial.

3

The use of calcium carbonate in nelfinavir-associated diarrhoea in HIV-1-infected patients.

Jensen-Fangel S, Justesen US, Black FT, Pedersen C, Obel N. Jensen-Fangel S, et al. Among authors: justesen us. HIV Med. 2003 Jan;4(1):48-52. doi: 10.1046/j.1468-1293.2003.00135.x. HIV Med. 2003. PMID: 12534959 Free article. Clinical Trial.

4

Therapeutic drug monitoring and human immunodeficiency virus (HIV) antiretroviral therapy.

Justesen US. Justesen US. Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):20-31. doi: 10.1111/j.1742-7843.2006.pto_246.x. Basic Clin Pharmacol Toxicol. 2006. PMID: 16433887 Free article. Review.

5

The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1,250 mg twice-daily regimen in HIV-infected patients.

Justesen US, Hansen IM, Andersen AB, Klitgaard NA, Black FT, Gerstoft J, Mathiesen LR, Pedersen C. Justesen US, et al. HIV Med. 2005 Sep;6(5):334-40. doi: 10.1111/j.1468-1293.2005.00317.x. HIV Med. 2005. PMID: 16156881 Free article. Clinical Trial.

6

Genotyping of CYP2B6 and therapeutic drug monitoring in an HIV-infected patient with high efavirenz plasma concentrations and severe CNS side-effects.

Mathiesen S, Justesen US, Von Lüttichau HR, Hansen AB. Mathiesen S, et al. Among authors: justesen us. Scand J Infect Dis. 2006;38(8):733-5. doi: 10.1080/00365540500504109. Scand J Infect Dis. 2006. PMID: 16857630

7

Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients.

Justesen US, Andersen AB, Klitgaard NA, Brøsen K, Gerstoft J, Pedersen C. Justesen US, et al. Clin Infect Dis. 2004 Feb 1;38(3):426-9. doi: 10.1086/380794. Epub 2004 Jan 12. Clin Infect Dis. 2004. PMID: 14727216 Clinical Trial.

8

Diurnal variation of plasma protease inhibitor concentrations.

Justesen US, Pedersen C. Justesen US, et al. AIDS. 2002 Dec 6;16(18):2487-9. doi: 10.1097/00002030-200212060-00019. AIDS. 2002. PMID: 12461428 Clinical Trial. No abstract available.

9

Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers.

Justesen US, Klitgaard NA, Brosen K, Pedersen C. Justesen US, et al. Br J Clin Pharmacol. 2003 Jan;55(1):100-6. doi: 10.1046/j.1365-2125.2003.01734.x. Br J Clin Pharmacol. 2003. PMID: 12534646 Free PMC article. Clinical Trial.

10

Dose-dependent pharmacokinetics of delavirdine in combination with amprenavir in healthy volunteers.

Justesen US, Klitgaard NA, Brosen K, Pedersen C. Justesen US, et al. J Antimicrob Chemother. 2004 Jul;54(1):206-10. doi: 10.1093/jac/dkh252. Epub 2004 May 18. J Antimicrob Chemother. 2004. PMID: 15150174 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

147 results

Search Page

Filters